• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腺相关病毒(AAV)和重组AAV载体的整合。

Integration of adeno-associated virus (AAV) and recombinant AAV vectors.

作者信息

McCarty Douglas M, Young Samuel M, Samulski R Jude

机构信息

School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA.

出版信息

Annu Rev Genet. 2004;38:819-45. doi: 10.1146/annurev.genet.37.110801.143717.

DOI:10.1146/annurev.genet.37.110801.143717
PMID:15568995
Abstract

The driving interest in adeno-associated virus (AAV) has been its potential as a gene delivery vector. The early observation that AAV can establish a latent infection by integrating into the host chromosome has been central to this interest. However, chromosomal integration is a two-edged sword, imparting on one hand the ability to maintain the therapeutic gene in progeny cells, and on the other hand, the risk of mutations that are deleterious to the host. A clearer understanding of the mechanism and efficiency of AAV integration, in terms of contributing viral and host-cell factors and circumstances, will provide a context in which to evaluate these potential benefits and risks. Research to date suggests that AAV integration in any context is inefficient, and that the persistence of AAV gene delivery vectors in tissues is largely attributable to episomal genomes.

摘要

对腺相关病毒(AAV)的主要兴趣在于其作为基因递送载体的潜力。早期观察到AAV可通过整合到宿主染色体中来建立潜伏感染,这一观察结果一直是人们对其产生兴趣的核心。然而,染色体整合是一把双刃剑,一方面赋予了在子代细胞中维持治疗性基因的能力,另一方面也带来了对宿主有害的突变风险。更清楚地了解AAV整合的机制和效率,包括相关的病毒和宿主细胞因子及情况,将为评估这些潜在益处和风险提供背景。迄今为止的研究表明,在任何情况下AAV整合效率都很低,并且AAV基因递送载体在组织中的持久性很大程度上归因于游离型基因组。

相似文献

1
Integration of adeno-associated virus (AAV) and recombinant AAV vectors.腺相关病毒(AAV)和重组AAV载体的整合。
Annu Rev Genet. 2004;38:819-45. doi: 10.1146/annurev.genet.37.110801.143717.
2
Chromosomal latency and expression at map unit 96 of a wild-type plus adeno-associated virus (AAV)/Neo vector and identification of p81, a new AAV transcriptional promoter.野生型腺相关病毒(AAV)/Neo载体在96图距单位处的染色体潜伏与表达以及新型AAV转录启动子p81的鉴定。
J Hum Virol. 1999 Nov-Dec;2(6):359-68.
3
Targeted integration of transfected and infected adeno-associated virus vectors containing the neomycin resistance gene.靶向整合含有新霉素抗性基因的转染和感染腺相关病毒载体。
Gene Ther. 1994 May;1(3):165-9.
4
Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells.重组腺相关病毒2基因组在人类细胞中缺乏位点特异性整合。
Hum Gene Ther. 1997 Feb 10;8(3):275-84. doi: 10.1089/hum.1997.8.3-275.
5
Adeno-associated virus integration: virus versus vector.腺相关病毒整合:病毒与载体
Gene Ther. 2008 Jun;15(11):817-22. doi: 10.1038/gt.2008.55. Epub 2008 Apr 10.
6
Targeted integration of a rAAV vector into the AAVS1 region.靶向整合 rAAV 载体到 AAVS1 区域。
Virology. 2012 Nov 25;433(2):356-66. doi: 10.1016/j.virol.2012.08.015. Epub 2012 Sep 13.
7
Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line.重组腺相关病毒(AAV-CFTR)载体不会以位点特异性方式整合到永生化上皮细胞系中。
Gene Ther. 1996 Sep;3(9):748-55.
8
Stable transduction of large DNA by high-capacity adeno-associated virus/adenovirus hybrid vectors.高容量腺相关病毒/腺病毒杂交载体对大片段DNA的稳定转导
Virology. 2004 Apr 10;321(2):287-96. doi: 10.1016/j.virol.2004.01.007.
9
Quantitative analysis of the packaging capacity of recombinant adeno-associated virus.重组腺相关病毒包装能力的定量分析
Hum Gene Ther. 1996 Nov 10;7(17):2101-12. doi: 10.1089/hum.1996.7.17-2101.
10
Adeno-associated virus Rep-mediated targeting of integrase-defective retroviral vector DNA circles into human chromosome 19.腺相关病毒 Rep 介导的整合酶缺陷型逆转录病毒载体 DNA 环靶向整合到人染色体 19 上。
Biochem Biophys Res Commun. 2012 Jan 6;417(1):78-83. doi: 10.1016/j.bbrc.2011.11.059. Epub 2011 Nov 22.

引用本文的文献

1
Trends and challenges of AAV-delivered gene editing therapeutics for CNS disorders: Implications for neurodegenerative disease.用于中枢神经系统疾病的腺相关病毒介导的基因编辑疗法的趋势与挑战:对神经退行性疾病的启示
Mol Ther Nucleic Acids. 2025 Jul 17;36(3):102635. doi: 10.1016/j.omtn.2025.102635. eCollection 2025 Sep 9.
2
Strategic Advances in Targeted Delivery Carriers for Therapeutic Cancer Vaccines.治疗性癌症疫苗靶向递送载体的战略进展
Int J Mol Sci. 2025 Jul 17;26(14):6879. doi: 10.3390/ijms26146879.
3
Exploring AAV-Mediated Gene Therapy for Inner Ear Diseases: from Preclinical Success to Clinical Potential.
探索腺相关病毒介导的内耳疾病基因治疗:从临床前成功到临床潜力
Adv Sci (Weinh). 2025 Sep;12(33):e08397. doi: 10.1002/advs.202408397. Epub 2025 Jun 20.
4
Advances in viral vector-based delivery systems for gene therapy: a comprehensive review.基于病毒载体的基因治疗递送系统的进展:全面综述。
3 Biotech. 2025 Jul;15(7):196. doi: 10.1007/s13205-025-04366-7. Epub 2025 May 30.
5
Engineering adeno-associated viral vectors for CRISPR/Cas based in vivo therapeutic genome editing.工程化腺相关病毒载体用于基于CRISPR/Cas的体内治疗性基因组编辑
Biomaterials. 2025 Oct;321:123314. doi: 10.1016/j.biomaterials.2025.123314. Epub 2025 Apr 2.
6
Detection of mRNA Transcript Variants.mRNA转录变体的检测
Genes (Basel). 2025 Mar 16;16(3):343. doi: 10.3390/genes16030343.
7
Adeno-Associated Virus Vectors: Principles, Practices, and Prospects in Gene Therapy.腺相关病毒载体:基因治疗的原理、实践与前景
Viruses. 2025 Feb 9;17(2):239. doi: 10.3390/v17020239.
8
Pilocytic astrocytoma in a child with spinal muscular atrophy treated with onasemnogene abeparvovec.接受onasemnogene abeparvovec治疗的脊髓性肌萎缩症患儿的毛细胞型星形细胞瘤
Mol Ther. 2025 Jun 4;33(6):2842-2850. doi: 10.1016/j.ymthe.2025.02.025. Epub 2025 Feb 15.
9
Cryo-EM structure of AAV2 Rep68 bound to integration site AAVS1: insights into the mechanism of DNA melting.与整合位点AAVS1结合的AAV2 Rep68的冷冻电镜结构:对DNA解链机制的深入了解
Nucleic Acids Res. 2025 Jan 24;53(3). doi: 10.1093/nar/gkaf033.
10
Oxidized mRNA Lipid Nanoparticles for Chimeric Antigen Receptor Monocyte Engineering.用于嵌合抗原受体单核细胞工程的氧化mRNA脂质纳米颗粒
Adv Funct Mater. 2024 Jul 3;34(27). doi: 10.1002/adfm.202312038. Epub 2024 Mar 5.